HSBC/CALL/FRESENIUS/40/0.1/18.12.24 Stock

Warrant

DE000TT5ZEK2

Market Closed - BOERSE MUENCHEN 15:37:16 2024-05-31 EDT
0.015 EUR -.--% Intraday chart for HSBC/CALL/FRESENIUS/40/0.1/18.12.24
3 months-25.00%
6 months-80.26%
Date Price Change
24-05-31 0.015 -.--%
24-05-30 0.015 -.--%
24-05-29 0.015 -.--%
24-05-28 0.015 -.--%
24-05-27 0.015 -.--%

Real-time BOERSE MUENCHEN

Last update May 31, 2024 at 03:37 pm

More quotes

Static data

Product typeWarrant Plain-Vanilla
Buy / SellCALL
Underlying FRESENIUS SE & CO. KGAA
Issuer HSBC
WKN TT5ZEK
ISINDE000TT5ZEK2
Date issued 2021-03-09
Strike 40
Maturity 2024-12-18 (199 Days)
Parity 10 : 1
Emission price 0.48
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.13
Lowest since issue 0.011
Spread 0.016
Spread %61.54%

Company Profile

Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - hospital administration and engineering (64.3%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (35.7%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (72.4%), North America (12.3%), Asia/Pacific (7.3%), Latin America (6.4%) and Africa (1.6%).
Sector
-
More about the company

Ratings for Fresenius SE & Co. KGaA

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Fresenius SE & Co. KGaA

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
29.28 EUR
Average target price
36.72 EUR
Spread / Average Target
+25.43%
Consensus